Evogliptin

依沃格列汀

Report date: 2026/03/28 20:00:32
NME

Base Information

Drug NameEvogliptin
Drug Alias Name依格列汀evogliptinaevogliptinumSuganonSUGANON +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsAortic valve diseasesLiver DysfunctionDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2015/10/02
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDong-A Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLuye Pharma Group LtdDong-A ST Co LtdDong-A Pharmaceutical Co Ltd
Inactive CompaniesREDNVIA Co Ltd
Active IndicationsAortic valve diseasesDiabetes Mellitus, Type 2
Inactive IndicationsLiver DysfunctionRenal Insufficiency

Other Information

ATC CodeA10BH07
Related LinksWikipediaDrugBankKEGG